Quest for Growth Belgium Overview
Quest for Growth is one of Belgium's few listed private-equity-style vehicles open to retail investors. As a public privak it offers daily-tradable, tax-efficient exposure to three segments: European listed small- and mid-caps (≈59% of NAV at mid-2026), venture and growth funds largely managed by Capricorn Partners (≈31%), and direct venture/growth investments (≈9%), across three themes — digital, healthtech and cleantech. After a difficult 2022–2025 period in venture valuations, the fund announced a strategic reorientation in late 2025 back to its founding mission, trimming large-cap listed positions and returning EUR 1 per share (EUR 18.7M) via a capital reduction in March 2026. Co-founder Jos Peeters became reference shareholder in 2025 after buying Belfius Insurance's stake. The shares trade at a historically wide discount of around 50% to NAV, versus a ten-year average near 27%.
Company's own description
In its NAV releases, Quest for Growth describes its diversified portfolio as mostly invested in growth companies listed on European stock exchanges, in venture and growth capital, and in venture and growth funds, focusing on innovative companies. Its 2026 investor material lists the investment case as diversified segments, diversified themes (cleantech, healthtech, digitalisation), daily tradability, favourable public-privak tax status, and a significant discount to NAV (analyst presentation, 31 Jul 2026).
Business model and "revenue" model
| Income line | FY2023 (EUR Mn) | FY2024 (EUR Mn) | FY2025 (EUR Mn) |
|---|---|---|---|
| Net realised gains/(losses) on financial assets | -6.19 | -5.77 | 4.00 |
| Net unrealised gains/(losses) | 2.48 | -0.28 | -6.26 |
| Dividend income | 1.82 | 2.16 | 2.14 |
| Net interest income | 0.08 | 0.14 | 0.05 |
| Total income from investments | -1.80 | -3.75 | -0.08 |
QFG earns returns, not sales. Its income consists of:
(FY2025 annual results press release.) Costs are dominated by a flat management fee to Capricorn Partners (EUR 1.48M p.a. in 2023–2025). There is no product, subscription or licensing revenue.
Value-chain position, customers, end-markets
QFG is a capital provider: (i) a minority portfolio investor in listed European small/mid-caps; (ii) a limited partner in Capricorn-managed funds (and selectively third-party funds such as Fortino Ventures III); (iii) a co-investor alongside those funds in direct venture rounds. Its "customers" are its shareholders — largely Belgian retail investors seeking tax-efficient access to private markets. End-markets of portfolio companies: industrial technology, healthcare/medtech, software/AI, cleantech and sustainable chemistry.
Independent characterisation
QFG is a sub-scale (≈EUR 110M NAV) closed-end fund whose fixed management fee (~1.4–1.5% of NAV) and persistent discount have weighed on shareholder returns: the ten-year share holding-period return to 30 Jun 2026 was −20.4%, versus +13.9% for NAV (analyst presentation). Its strongest asset is a disciplined listed-equity book with long-term winners (Nexus, Melexis, Wolters Kluwer); its weakest is a venture/fund book heavily exposed to cleantech and SaaS valuations, which has been marked down repeatedly. The late-2025 capital return and reorientation are a direct response to the discount problem.
Strategy
Stated themes (FY2025 release; HY 2026 presentation): return to the original mission of giving every shareholder tax-efficient, tradable access to diversified unlisted growth companies (directly and via funds) plus successful listed small/mid-caps; three segments; three themes (cleantech, healthtech, digitalisation).
No numerical medium-term targets or NAV/dividend guidance are published. Dividend policy: no dividend for FY2025 given the loss and carried-forward losses.
Products & Services
Quoted equities (known positions, 2025–2026)
| Company | Country | Description | Status / data |
|---|---|---|---|
| Nedap | NL | Technology (healthcare, livestock, retail, security; software ≈40% of revenue) | Held; +72% in 2025 |
| Norbit | NO | Sonar (Oceans), road-toll systems, industrial electronics | Added Apr 2025; ~+55% |
| Beijer Alma | SE | Industrial springs (Lesjöfors) | Added 2025; +51% |
| Andritz | AT | Industrial equipment | Held; +43% in 2025 |
| Jensen-Group | BE | Industrial laundry equipment | Held; +39% in 2025 |
| INIT | DE | Public-transport software | Held; +30% in 2025 |
| Arcadis | NL | Infrastructure consultancy | Added 2025 (small); −26% |
| De'Longhi | IT | Coffee machines | Added 2025 |
| Mensch und Maschine | DE | CAD/CAM software | Added 2025 (small) |
| Schott Pharma | DE | Drug containment/delivery (syringes, cartridges, vials); market cap ~EUR 2.6B | New 2026 (top-10) |
| SP Group | DK | Custom polymer parts for healthcare/cleantech/industry; ~EUR 640M | New 2026 |
| Krones | DE | Beverage filling/packaging; ~EUR 4.3B | New 2026 |
| Kerry Group | IE | Food ingredients (~EUR 13B; 2nd largest position) | Exited H1 2026 |
| Melexis | BE | Automotive semiconductors | Exited H1 2026 (+1,300% since 2011) |
| Wolters Kluwer, Roche, Nexus, Financière de Tubize, Datron, ABO Energy | Various | — | Exited 2025 |
Direct venture & growth capital
| Company | Country | Sector | Latest activity |
|---|---|---|---|
| Gradyent | NL | AI for district heating/energy networks | EUR 1.5M in EUR 28M round (2025), led by Blue Earth Capital |
| EclecticIQ | NL | Cyber threat intelligence | Internal rounds 2025 and EUR 100k in EUR 1.75M round (2026) |
| DMC Biotechnologies | US | Biomanufacturing | USD 110k in USD 7.8M round (Apr 2026) |
| fruitcore robotics | DE | Industrial robotics | EUR 75k in EUR 2.85M internal round (Q1 2026) |
| Rein4ced | BE | Composite bike frames | Bankrupt end-2025 |
| Others | — | — | Not individually retrieved |
Undisclosed valuation changes in V&G capital: −1.4% of segment (H1 2026 presentation).
Venture & growth funds (share of NAV at 30 Jun 2026 where shown)
| Fund | Theme | Commitment / activity | Notable underlying |
|---|---|---|---|
| Capricorn Digital Growth Fund | Digital | Calls EUR 3.5M (2025), EUR 2.4M (H1 2026) | Azumuta, Conxai (EUR 2.0M), Rocsys (EUR 3.5M), Gradyent, EclecticIQ |
| Capricorn Healthtech Fund II | Health | Commitment raised from EUR 12.5M to EUR 15M (2025); calls EUR 0.8M (2025), EUR 2.5M (H1 2026); fund size EUR 62M → EUR 89M | Aspect Analytics, Xyall (EUR 3.0M), Oska Health (EUR 2.0M), EndoTools (EUR 5.0M, Q3 2026) |
| Capricorn Healthtech Fund (I) | Health | Legacy | — |
| Capricorn SCF (Sustainable Chemistry) | Cleantech | Calls EUR 0.6M (2025), EUR 0.8M (H1 2026) | DMC, Zeopore, Econic, Rein4ced |
| Capricorn Fusion China Fund | Diversified | Calls EUR 0.2M (2025 and H1 2026) | Spectricity, fruitcore robotics |
| Capricorn ICT Arkiv | Digital | Distribution EUR 2.0M (H1 2026, of which EUR 0.5M dividend) | Icometrix (sold to GE Healthcare) |
| Fortino Ventures III | B2B SaaS/AI | EUR 2M committed May 2026; EUR 0.2M called | mkind, Polysense.ai, Birdsview.com |
| Life Sciences Partners IV | Life sciences | Final EUR 0.5M distribution Dec 2025 | Fully realised |
Financial Narrative
Currency EUR. For an investment fund, "revenue" = total income from investments; "operating income" = profit from operating activities. EBITDA, gross profit, capex and cash conversion cycle are not meaningful.
Income statement
Sources: FY2022 release (FY2021–22), FY2025 release (FY2023–25), Annual Report 2025 (dividend history). FY2025 ROE uses NAV adjusted to add back the EUR 18.73M capital-repayment liability. Margins (gross/operating/net) are not meaningful because income is negative or near zero in FY2023–FY2025. "Revenue CAGR" not meaningful.
Commentary. FY2021 was the last strong year (+21.9% ROE). Since then, rising rates crushed growth valuations (2022), and venture/fund marks deteriorated each year from 2023 to 2025. The listed book has been the stabiliser (+18% gross in 2025, in line with STOXX Europe Small 200), but the fixed fee (~EUR 1.5M) consumes most dividend income, so positive NAV returns depend on capital gains.
Balance sheet
FY2025 "other liabilities" includes the EUR 18,733,961 capital distribution payable; NAV per share 7.05 adds this back (unadjusted equity/share ≈ EUR 6.05). QFG is debt-free.
Cash flow and capital returns
FY2021 dividend total EUR 19.05M (ordinary EUR 17.08M + preference EUR 1.97M), paid April 2022 (Annual Report 2025 key figures). Capital reduction decided Dec 2025, paid 23 Mar 2026. Operating cash flow and capex in the classic sense not applicable.
Monthly NAV and price, 2026 (NAV press releases)
Discrepancy note: March NAV appears as EUR 5.51 (April release) and EUR 5.50 (later tables); March discount appears as 48.2% and 48.3% in different tables. The drop from February to March reflects the EUR 1 capital repayment (ex-date ~19–23 Mar 2026) plus the Q1 software sell-off.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Themes |
|---|---|---|
Quoted equities | European listed small/mid-caps (some larger caps being reduced) | Industrial tech, healthcare, digital |
Venture & growth capital (direct) | Minority stakes, mostly co-investments with Capricorn funds | Digital, health, cleantech |
Venture & growth funds | LP commitments: Capricorn Digital Growth Fund, Capricorn Healthtech Fund (I & II), Capricorn SCF, Capricorn Fusion China Fund, Capricorn ICT Arkiv, Fortino Ventures III, others | Digital, health, cleantech, diversified |
Segment income (EUR Mn)
| Segment income (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Quoted equities | 5.38 | 2.56 | 12.64 |
Venture & growth capital (direct) | -1.82 | -3.54 | -3.95 |
Venture & growth funds | -5.44 | -2.91 | -8.81 |
Total income from investments | -1.80 | -3.75 | -0.08 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Segment (% of portfolio) | 31 Dec 2025 | 30 Jun 2026 |
|---|---|---|
Quoted equities | 57.7 | 58.7 |
Venture & growth capital | 8.0 | 8.7 |
Venture & growth funds | 23.9 | 31.3 |
Cash and other net assets | 10.3 | 1.3 |
Dividends & Capital Returns and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total income from investments (EUR Mn) | — | — | -1.80 | -3.75 | -0.08 |
Dividend income (EUR Mn) | — | — | 1.82 | 2.16 | 2.14 |
Total operating expenses (EUR Mn) | — | — | -2.24 | -1.98 | -2.04 |
of which management fee (EUR Mn) | — | — | -1.48 | -1.48 | -1.48 |
Profit from operating activities (EUR Mn) | — | — | -3.18 | -5.89 | -2.06 |
Pre-tax result (EUR Mn) | — | — | -3.18 | -5.89 | -2.06 |
Net result (EUR Mn) | 33.14 | -24.83 | -3.52 | -6.34 | -2.42 |
EPS basic = diluted (EUR) | 1.98 | -1.40 | -0.19 | -0.34 | -0.13 |
Gross dividend per ordinary share for the year (EUR) | 1.02 | 0 | 0 | 0 | 0 |
Return on equity (%) | 21.87 | -14.70 | -2.44 | -4.50 | -1.80 |
Key Financials and Margin Analysis (%)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Net result (EUR Mn) | 3.8 | -3.4 |
Q2 result (EUR Mn) | — | 6.9 |
Return on NAV (%) | 2.83 | -2.3 |
NAV per share, period end (EUR) | — | 5.86 |
Share price, period end (EUR) | 4.04 | 2.99 |
Discount (%) | 45.2 | 49.0 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR Mn) | — | — | 140.78 | 134.46 | 132.04 |
Cash and equivalents (EUR Mn) | — | — | 6.80 | 3.38 | 12.83 |
Financial assets at FVTPL — equity (EUR Mn) | — | — | 132.80 | 130.24 | 118.24 |
Total debt (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt (EUR Mn) | — | — | -6.80 | -3.38 | -12.83 |
Equity attributable to shareholders (EUR Mn) | — | — | 140.74 | 134.41 | 113.25 |
Other liabilities (EUR Mn) | — | — | 0.04 | 0.05 | 18.79 |
Goodwill and intangibles (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
NAV per share (EUR) | 10.71 | 7.93 | — | 7.17 | 7.05 |
Average shares outstanding (M) | — | — | 17.77 | 18.60 | 18.73 |
Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends declared for year (EUR Mn) | 19.05 | 0 | 0 | 0 | 0 |
Capital returned via reduction (EUR Mn) | 0 | 0 | 0 | 0 | 18.73 |
Buybacks (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (%) | -4.50 | -1.80 |
ROA (net result / avg assets) (%) | -4.6 | -1.8 |
Operating expense ratio (opex / avg NAV) (%) | 1.4 | 1.5 |
Management fee / avg NAV (%) | 1.1 | 1.1 |
Debt/equity (x) | 0 | 0 |
Financial Analysis
| Metric | Feb26 | Mar26 | Apr26 | May26 | Jun26 | Jul26 | Aug26 | Sep26 |
|---|---|---|---|---|---|---|---|---|
NAV per share (EUR) | 6.98 | 5.51 | 5.82 | 5.96 | 5.86 | 5.96 | 6.04 | 5.82 |
Share price (EUR) | 4.42 | 2.85 | 2.95 | 3.00 | 2.99 | 2.97 | 3.03 | 2.79 |
Discount (%) | 36.6 | 48.2 | 49.3 | 49.7 | 49.0 | 50.1 | 49.8 | 52.1 |
Share Price and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price (EUR) | 7.98 | 6.00 | — | 3.98 | 4.19 |
NAV per share (EUR) | 10.71 | 7.93 | — | 7.17 | 7.05 |
Discount (%) | 25.5 | 24.3 | — | 44.5 | 40.5 |
Gross dividend per share (EUR) | 1.02 | 0 | 0 | 0 | 0 |
Analyst Conclusions
Guidance: none quantitative. Management highlights attractive small-cap valuations, cautious optimism on venture in 2026, and the discount as an entry opportunity.
Bull case
-
A ~52% discount means the market values the listed book alone (~59% of NAV ≈ EUR 64M) above the entire market cap (~EUR 52M) — the unlisted book is effectively free.
-
Rotation into low-P/E industrial quality names (Krones 10.3x, SP Group 11.4x) plus small-cap mean reversion could drive NAV growth.
-
Exits from Capricorn funds (Icometrix precedent) and recovering software multiples could reverse venture write-downs.
Bear case
-
Four straight loss years and fixed fees leave little margin for error.
-
Venture/cleantech exposure keeps producing write-downs and failures.
-
Without buybacks or further distributions, the discount may stay structurally wide.
Catalysts (12 months): monthly NAVs; FY2026 results (late Jan 2027); details and effect of the new remuneration policy; any buyback/distribution decision; fund exits; small-cap market direction.
Analyst verdict. Quest for Growth offers something rare in Belgium — a listed, tax-efficient route into venture and growth capital combined with a well-run small/mid-cap equity book. Its record in listed stocks is genuinely strong, with multi-bagger holdings such as Nexus and Melexis. The problem has been everything around that core: venture and cleantech fund marks have deteriorated for several years, the fixed management fee absorbs most dividend income, and the discount to NAV has roughly doubled from its historical norm, leaving long-term shareholders with negative ten-year returns even as NAV grew modestly.
The late-2025 reorientation, the EUR 1 per share capital return, the arrival of a co-founder as reference shareholder and a slimmer board show that governance is responding. But the H1 2026 numbers illustrate the fragility: a single quarter of software-multiple compression erased the 2025 listed gains, and the discount widened further to 52% by September 2026.
At around 0.48x NAV, the shares price in substantial pessimism — the quoted portfolio alone exceeds the market capitalisation. For a patient investor, that is a margin of safety. Yet discounts on small closed-end funds can persist for years without a catalyst. We would want to see concrete discount-control measures (buybacks, regular distributions, or fee alignment under the new policy) and stabilisation of venture valuations before turning positive.
Our stance: speculative value. The most important monitorables are the terms of the new remuneration policy, any capital-return decisions at the FY2026 results, and whether Capricorn fund exits begin to crystallise value above carrying marks.
Sources: QFG annual results 2025 press release (29 Jan 2026); Annual Report 2025 (NL/FR); AGM 2025 and 2026 proxies; semi-annual reports 30 Jun 2025 and 30 Jun 2026; press & analyst meeting 31 Jul 2026; monthly NAV releases (Apr–Oct 2026); FY2022 annual results release; shareholder-structure and team pages (capricorn.be); Parqet (secondary, flagged).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Notes |
|---|---|---|
Lieve Creten | Chair | Independent status not confirmed in documents reviewed |
Sabine Vermassen | Director; Executive Officer | Managing Partner, Capricorn Partners |
Jos B. Peeters | Director (nominated by preference shareholders per 2026 proxy) | Co-founder; reference shareholder (≈12.8%) |
Thierry François | Director | Joined 2026, replacing Philippe de Vicq and Jos Clijsters |
Véronique Léonard | Director | — |
Paul Van Dun | Director | — |
Executive Leadership Team
| Name | Role |
|---|---|
Steven Levecke | Executive Officer; Managing Partner; unquoted portfolio |
Sabine Vermassen | Executive Officer; Managing Partner |
Jan Avonts | Investment Director; quoted portfolio |
Jelle Van de Putte | Fund Administrator |
Kim De Keyser | Valuation Expert |
Major Shareholders
| Holder | Shares | % | Date |
|---|---|---|---|
Jos B. Peeters | 2,398,238 | ≈12.8 (derived) | 31 Dec 2025 |
Belfius Insurance | 0 (sold) | previously 11.98 | Jun 2025 |
Philippe Haspeslagh | Co-acquirer of Belfius stake; individual stake below threshold (not disclosed) | — | 2025 |
Free float | ≈87 | — | derived |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap | Positioning vs QFG |
|---|---|---|---|
Gimv | Listed Belgian investment company | Growth/buyout, health, sustainability | Far larger; direct deals |
Sofina | Listed Belgian holding | Growth/VC funds | Far larger; global VC |
Brederode | Listed Belgian/Lux holding | PE funds + listed | Larger; fund-of-funds model |
Ackermans & van Haaren | Listed Belgian holding | Diversified | Much larger |
TINC | Listed Belgian public privak | Same tax status, infrastructure | Comparable legal wrapper, different asset class |
Smartfin, Volta Ventures, Inventures | Belgian VC funds | Venture | Unlisted, institutional |
PMV / SFPI-FPIM | Public investors | Belgian venture/growth | Co-investors and competitors for deals |
Belgian small-cap equity funds (bank-managed) | Mutual funds | Listed small/mid-caps | Daily NAV liquidity, no discount |
European listed growth/VC trusts | Listed funds | Venture/growth access | Larger, pan-European |
Competitor Detail
| Benchmark | QFG FY2025 |
|---|---|
NAV (EUR Mn, adjusted) | ≈132 |
ROE (%) | -1.8 |
Discount (%) | 40.5 |
Opex ratio (%) | ≈1.5 |



